摘要
目的探讨贝伐珠单抗联合长春瑞滨对宫颈癌的疗效及预后的影响。方法选择2021年1月—2022年6月期间南阳市中心医院收治的100例宫颈癌为研究对象,随机分成对照组50例与观察组50例,分组方法为随机数字表法。长春瑞滨应用于对照组患者治疗中,贝伐珠单抗^(+)长春瑞滨应用于观察组治疗中。治疗后,观察疗效,对比两组的肿瘤特异性生长因子(tumor specific growth factor,TSGF)鳞状细胞癌抗原(squamous cell carcinoma antigen,SCC-Ag)与细胞角蛋白19片段抗原21-1(cytokeratin 19 fragment antigen 21-1,CYFRA21-1),比较两组免疫指标水平、不良反应发生情况、生存率。结果观察组较对照组临床疗效显著提高[观察组vs对照组:86.00%(43/50)vs 66.00%(33/50)(P<0.05)];治疗后,两组患者SCC-Ag、TSGF、CYFRA21-1水平均降低,且观察组水平较低(P<0.05);治疗完毕后,两组CD3^(+)、CD4^(+)水平有所上升,CD8^(+)水平有所降低,其中观察组改善幅度更大(P<0.05);观察组较对照组不良反应发生情况显著降低[观察组vs对照组:8.00%(4/50)vs 24.00%(12/50)](P<0.05);随访一年,观察组3、6、12个月的总生存率高于对照组。结论联合治疗能够改善患者的免疫功能,具有较好的治疗效果,远期生存率提高且安全性较高。
Objective To analyze the effect and prognosis of bevacizumab combined with vinorelbine on cervical cancer.Methods From January 2021 to June 2022,100 cases of cervical cancer in the Nanyang Central Hospital were selected and randomly divided into control group(50 cases)and observation group(50 cases).The grouping method was random number table method.Vinorelbine was used in the treatment of patients in the control group,and bevacizumab+vinorelbine was used in the treatment of observation group.After treatment,the curative effect was observed,and the tumor specific growth factor(TSCF),squamous cell carcinoma antigen(SCC-Ag)and cytokeratin 19 fragment antigen 21-1(CYFRA21-1)were compared between the two groups,and the immune index level,adverse reactions and survival rate were compared.Results The clinical efficacy of the observation group was significantly improved compared with the control group[observation group vs control group:86.00%(43/50)]vs 66.00%(33/50)(P<0.05)J;after treatment,the levels of SCC-Ag,TSCF and CYFRA21-1 in two groups were decreased,and the levels in observation group were lower than those of the control group(P<0.05);after treatment,CD3^(+)and CD4^(+)levels increased and CD8^(+)levels decreased in the two groups,with the improvement in the observation group(P<0.05);the occurrence of adverse reactions in the observation group was significantly lower than that in the control group[observation group vs control group:8.00%(4/50)vs 24.00%(12/50)],and the difference was statistically significant(P<0.05);the 0verall survival rate at 3,6 and 12 months in the observation group was higher than that in the control group.Conclusion Combined therapy can improve the immune function of patients,has a good therapeutic effect,long-term survival rate and high safety.
作者
李英霞
汪爱兵
杨然
杨冉
左燕雨
李文明
LI Ying-xia;WANG Ai-bing;YANG Ran;YANG Ran;ZUO Yan-yu;LI Wen-ming(the Second Ward of Gynecological Department,Nanyang Central Hospital,Nanyang,Henan 473000,China;Department of Thoracic Medical Oncology,Nanyang Central Hospital,Nanyang,Henan 473000,China)
出处
《医药论坛杂志》
2025年第13期1429-1432,1437,共5页
Journal of Medical Forum
